


Vitamin K Another Calcification Nutrient to Consider?

Sarah L. Booth, Ph.D.
Associate Director and Senior Scientist
Director, Vitamin K Laboratory

Vitamin K and Calcification


- Forms of vitamin K
- Dietary intakes and requirements
- Role in regulation of calcification
- Evidence for vitamin K interactions with vitamin D

Implications



Overview of Vitamin K Forms

Vitamin K Forms




Dietary Sources of Menaquinones (Has not been systematically analyzed in the US food supply)

| Food | n | K1 | MK-4 | MK-5 | MK-6 | MK-7 | MK-8 | MK-9 |
|------------------|----|------|------|------|------------------|------|------|------|
| | | | | | μ g/100 g | | | |
| Natto | 5 | 34.7 | - | 7.5 | 13.8 | 998 | 84.1 | - |
| Buttermilk | 6 | - | 0.2 | 0.1 | 0.1 | 0.1 | 0.6 | 1.4 |
| Whole Yoghurt | 6 | 0.4 | 0.6 | 0.1 | - | - | 0.2 | - |
| Hard Cheeses | 15 | 10.4 | 4.7 | 1.5 | 0.8 | 1.3 | 16.9 | 51.1 |
| Soft Cheeses | 15 | 3.6 | 2.7 | 0.3 | 0.5 | 1.0 | 11.4 | 39.6 |
| Curd Cheese | 12 | 0.3 | 0.4 | 0.1 | 0.2 | 0.3 | 5.4 | 18.7 |
| Egg Yolk | 8 | 2.1 | 31.4 | - | 0.7 | - | - | - |

Schurgers L, Vermeer C. Haemostasis 2000; 30:298-307

Dietary Supplements

- Phylloquinone is globally available as a dietary supplement
- MK-7 is globally available as a dietary supplement
- In Japan, MK-4 is used therapeutically in doses of 45,000 μg/day
- Combinations of Phylloquinone, MK-4 and MK-7 are available at doses considerably higher than is available from food
 - No data available on the potential interactions among vitamin K forms when co-administered




Dietary Intakes and Requirements of Vitamin K

Dietary recommended intakes (DRI) for vitamin K in adults

| | | DRI | | |
|--------------------------|-------|--------------------------------------|-------------|--|
| Country | Sex | (μg/day, unless otherwise indicated) | | |
| | | 19-50y | >51y | |
| UK | Women | 1 μg/(kg d) | 1 μg/(kg d) | |
| UK | Men | 1 μg/(kg d) | 1 μg/(kg d) | |
| WHO/ Bosnia/ | Women | 55 | 55 | |
| Herzegovina/Poland | Men | 65 | 65 | |
| Nov. Zoolovel /Avetualia | Women | 60 | 60 | |
| New Zealand /Australia | Men | 70 | 70 | |
| lanan | Women | 60, 65 ^b | 65 | |
| Japan | Men | 70 | 70 | |
| Germany/Switzerland/ | Women | 60 | 65 | |
| Austria | Men | 70 | 80 | |
| USA/Canada/ | Women | 90 | 90 | |
| Montenegro/ Albania | Men | 120 | 120 | |

Evidence of Adverse Events

- No recorded evidence with phylloquinone or MK-4 among individuals with normal clotting function
- Any vitamin K form will interfere with efficacy of coumarin-based oral anticoagulants (eg. warfarin)
- Some indication that MK-7 may interfere with oral anticoagulants at a much lower dose compared to phylloquinone and MK-4




What does this mean?

We do not know how much vitamin K is required for optimal health


 Current guidance: Eat a diet rich in vegetables and plant oils (DOES NOT APPLY TO PATIENTS ON WARFARIN)

Vitamin K Function

VK is critical for some proteins to function



Warfarin Interrupts Vitamin K Cycle



VK and bone: Disentangling the myths from facts



Why Consider Vitamin K in Bone Health?

- VK is in bone
- Important bone protein requires VK for function
- VK status rapidly responds to depletion and repletion
- VK intakes are low in certain subpopulations eg. UK children and elderly

Phylloquinone Intake & Bone: Observational Studies*

| Hypothesis | # of Studies In Support of Hypothesis | |
|----------------------------|--|----------------------------|
| | Yes | No |
| ↑ K1 intake → ↓ Hip fx | 3 (adults) | 2 (adults) |
| ↑K1 intake /plasma → ↑ BMD | 3 (adults) | 2 (children) 2 (adults) |

^{*} Cross-sectional and Longitudinal Designs

MK-7 Intake & Bone: Observational Studies*

| Hypothesis | # of Studies In Support of Hypothesis | |
|---------------------------------|--|--------------|
| | Yes | No |
| ↑ MK-7 intake/plasma → ↓ Hip fx | 2 (adults) | 1 (adults) |
| ↑ MK-7 intake/plasma→ ↑ BMD | 2 (adults) | - |
| ↑ MK-7 intake → ↓ bone turnover | | 1 (children) |

^{*} Cross-sectional and Longitudinal Designs

Phylloquinone Supplementation Studies

| Study | Control (C) | Duration | Difference in | Ref |
|-------------------------|------------------------------|----------|----------------|----------------------|
| | vs | (M) | Hip BMD | |
| | Treatment (T) | | | |
| Tufts | C: vit D + Ca | 36 | No difference | Booth |
| (M+F; 60-80y) | T: vit D + Ca + 500 μg K1 | | | JCEM 2008 |
| Maastricht | C: placebo | 36 | T < C; p <0.05 | Braam |
| (F; 50-60y) | T1: vit D + Ca | | | Calc Tiss Intl 2003 |
| | T2: vit D + Ca + 1,000 μg K1 | | | |
| Maastricht | C: placebo | 24 | No difference | Braam |
| (F; endurance athletes) | T1: 10,000 µg K1 | | | Am J Sports Med 2003 |
| Wisconsin | C: vit D + Ca | 12 | No difference | Binkley |
| (F; >55y) | T: vit D + Ca + 1,000 μg K1 | | | JBMR 2009 |
| UK Bones & | C: placebo | 24 | No difference | Bolton-Smith |
| Vitamins | T1: vit D + Ca + 200 μg K1 | | | JBMR 2007 |
| (F;>60y) | T2: 200 µg K1 | | | |
| ECKO | C: vit D + Ca | 24 | No difference | Cheung |
| (F;40-82y) | T: vit D + Ca + 5,000 μg K1 | | | PLoS Medicine 2008 |

MK-4 Supplementation Studies

| Study | Control (C) | Duration | | Ref |
|------------|----------------------------|----------|--|-----------------|
| | vs | (M) | Hip BMD | |
| | Treatment (T) | | | |
| Maastricht | C: placebo | 36 | No difference | Knapen |
| (F; 5575y) | T: 45 mg MK-4 | | (but there was improved femoral neck geometry) | Osteo Intl 2007 |
| Wisconsin | C: vit D + Ca | 12 | No difference | Binkley |
| (F; >55y) | T: vit D + Ca + 45 mg MK-4 | | | JBMR 2009 |

MK-4 + Calcium Does Not Reduce Fracture Risk Above That Of Calcium Alone

(Four-year trial of 4378 post-menopausal women)


Inoue et al *J Bone Miner Metab* 2009

MK-7 supplementation for three years does protect against bone loss

180 μg/d MK-7 (n=112) vs placebo (n= 111) – no calcium or VD in either group

F; 55-65y (postmenopausal)

* P<0.05; # P<0.001




What does this mean?

- Phylloquinone and MK-4 supplementation does not appear to reduce bone loss among adults who are calcium- and vitamin D-replete.
- MK-7 supplementation may modestly reduce bone loss among postmenopausal women who are not receiving calcium and vitamin D supplements.
- Need randomized clinical trials using MK-7 in calcium and vitamin D-replete populations.

The Role of Vitamin K in Pathological Calcification




Osteoporosis & Vascular Calcification: A Calcium Imbalance?




Schulz, E. et al J Clin Endo & Metab. 2004

Osteoporosis & Vascular Calcification:




Complex Molecular Processes Common to Both Bone and Vessels!




Pathological Calcification Associated with Low VK

| Tissue/Location | Disease outcome |
|--|-------------------------------------|
| Coronary arteries (atherosclerosis) | Coronary heart disease |
| Vascular (Monckeberg's sclerosis- medial layer) | Chronic kidney disease, Diabetes |
| Coronary valves | Aortic valve disease |
| Cartilage (chondrocalcinosis) | Osteoarthritis |

VK is critical for some proteins to function




MGP Knockout Mouse Model



Trachea and aorta is completely calcified


Osteopenia

Abnormal calcification of cartilage



Luo et al, Nature 1997

Central Hypothesis



Excessively High Amounts of the Active Form of Vitamin D causes Kidney Calcification

1, 25 (OH)₂D₃ causes kidney calcification in mice model

| | 1,25(OH) ₂ D ₃ (µg/kg diet) | | | |
|-------------------|---|------------|------------|--|
| | 0 | 2.5 | 5.0 | |
| %calcium deposits | 0/14 (0%) | 4/14 (28%) | 9/11 (82%) | |


Mernitz et al. 2007

1, 25 (OH)₂D₃ ↑ MGP and in the absence of vitamin K, ↑ non-functional MGP

| 1,25(OH) ₂ D ₃ (μg /kg diet) | Total MGP | Non Functional MGP: Functional MGP |
|---|-----------|---------------------------------------|
| 0 | 12.6 | 1:1 |
| 2.5 | 23.2 | 1.6:1 |
| 5.0 | 27.3 | 1.7:1 |


Fu et al. 2008

But We Do Not Consume Vitamin D in the Form of Calcitriol !!!!



Holick M NEJM 2007


Can we stop or even <u>regress</u> pre-formed arterial calcification with vitamin K?



37% reduction

Phylloquinone supplementation reduced coronary artery calcification progression

Mean (SEM) 3-year change in CAC in older men and women (60-80 yrs old); Vitamin D and calcium replete



What does this mean?


 Vitamin K appears to control progression of abnormal calcification

There is currently no evidence that very high vitamin
 D intake causes increased calcification in humans

 Current guidance: Eat a diet rich in vegetables and plant oils for vitamin K

Frequently Asked Questions Regarding Vitamin K and Vitamin D

- What is the best form of vitamin K to consume and how much should I consume?
- Is it important to consume vitamin K with vitamin D supplements?
- What is the right balance between calcium, vitamin D and vitamin K?



Thank you for listening, and feel free to email me at:

sarah.booth@tufts.edu





